FDA Approves Ensitrelvir for COVID-19 PEP

Key Takeaways

• Shionogi said FDA approved XOCOVA (ensitrelvir) for PEP in ages 12+ after COVID-19 exposure, ahead of a June 16, 2026 PDUFA date.
• SCORPIO-PEP showed a 67% reduction in symptomatic COVID-19 through day 10 versus placebo.
• NEJM published the household-contact Phase 3 results (NCT05897541).
• Adverse-event rates were similar to placebo in company summaries; check the label for interactions and lipids.

What is the approved ensitrelvir PEP use?

According to Shionogi’s May 31, 2026 Business Wire release, FDA approved ensitrelvir for PEP in adults and adolescents 12 and older after contact with someone who has COVID-19. Dosing is three tablets on day one and one tablet daily on days two through five.

How strong was the SCORPIO-PEP evidence?

NEJM’s SCORPIO-PEP report states ensitrelvir given within 72 hours of index-patient symptom onset prevented COVID-19 in household contacts. Company materials cite a 67% reduction in symptomatic disease through day 10 versus placebo.

Trial registration includes ClinicalTrials.gov NCT05897541.

Where did the U.S. filing stand before approval?

An earlier September 2025 Business Wire note said FDA accepted the PEP NDA with a PDUFA goal date of June 16, 2026. The May 2026 approval announcement said action came ahead of that date.

Why PEP still matters in 2026

Vaccination reduced severe disease, but household outbreaks continue. No prior oral antiviral had a clean U.S. PEP win. Monoclonal antibodies for prevention largely exited as variants shifted. An oral five-day course changes outbreak-response kits for long-term care and high-risk homes.

Expect protocols for nursing homes, transplant clinics, and household contacts of high-risk index patients. Timing windows matter: SCORPIO-PEP started therapy within 72 hours of index symptom onset.

How will payers and providers use ensitrelvir?

Formulary teams will compare course cost against vaccine-only strategies and against prevention antibodies that left the market. Contracting with long-term care pharmacies may matter more than retail alone. Pharmacists must screen CYP3A interaction lists and counsel on lipid lab shifts seen in earlier programs.

Public health messaging should keep vaccination primary. Ensitrelvir PEP is a post-exposure tool, not a substitute for immunization ahead of winter waves.

What remains unproven?

Real-world effectiveness against future variants is not locked by one Phase 3 season. EMA review for PEP or treatment may lag the U.S. decision. Do not confuse PEP approval with a new U.S. claim for treating established symptomatic infection without checking the current Prescribing Information.

Launch forecasts should separate household PEP volume from treatment courses abroad. Demand will spike with winter waves, then fall. Competitor oral protease inhibitors seeking PEP claims must clear the SCORPIO-PEP bar ensitrelvir set.

Hospitals should stock clear eligibility checklists so ensitrelvir PEP starts inside the proven exposure window rather than days later when household transmission risk has already peaked.

Medical affairs teams need one-page comparisons of PEP versus treatment dosing, age cutoffs at 12 years, and the five-day pack schedule for rapid staff education.

Payers may require documentation of a positive index case and timing of first contact before covering the course, mirroring how other outbreak antivirals were gated.

Surveillance for rebound symptoms and viral sequencing in breakthrough cases will refine how durable the 67% relative risk reduction remains against new variants.

Until those data mature, treat the approval as a major prevention option grounded in NEJM-reported Phase 3 evidence—not as proof that COVID-19 transmission is solved.

What safety signals did company materials report?

The May 31, 2026 Business Wire approval release said overall adverse-event rates were similar across arms: 15.4% with XOCOVA and 15.5% with placebo. Events occurring in more than 1% of the XOCOVA group and at a higher rate than placebo included headache, diarrhea, and cough, according to that company summary.

Sponsors and pharmacies still need the U.S. Prescribing Information for contraindicated drugs, lipid monitoring, and pregnancy counseling. Do not treat a press-release AE table as a substitute for the label.

How does Fast Track history relate to the early action?

A March 2025 Business Wire CROI readout stated FDA granted Fast Track designation in 2025 for ensitrelvir PEP after contact with an infected person. That designation can support more frequent agency interaction and rolling review; Shionogi later said the May 2026 approval arrived ahead of the June 16, 2026 PDUFA goal date.

Earlier Fast Track for treatment (2023) does not expand the new U.S. PEP indication. Keep treatment and prevention claims separate in BD models and medical-affairs decks.

What commercial questions should BD teams model now?

Price the five-day pack against avoided outpatient visits and short-stay admissions in high-risk households, not against full treatment courses used abroad. Volume will be seasonal and outbreak-driven.

Watch channel mix: long-term care pharmacies, retail chains with rapid test + antiviral pathways, and health-system specialty pharmacies. Contracting may require proof of a laboratory-confirmed index case and a start within the 72-hour window used in SCORPIO-PEP.

Related NovaPharma coverage

• XOCOVA first oral COVID-19 PEP coverage
• First oral COVID-19 PEP drug Xocova
• Moderna mRNA-1083 flu/COVID Phase 3 data

Frequently Asked Questions

Primary Sources

1. Business Wire — Shionogi FDA approval of ensitrelvir PEP
2. NEJM — Ensitrelvir postexposure prophylaxis
3. ClinicalTrials.gov NCT05897541 — SCORPIO-PEP
4. Business Wire — FDA NDA acceptance / PDUFA date